Apnimed
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
39 JFK St Fl 4, Cambridge, Massachusetts...Phone Number
(877) 276-4633Website
www.apnimed.comRevenue
$120.2 MillionStock Symbol
APMDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
2
2
1
About Apnimed
Apnimed is a clinicalstage biopharmaceutical company focused on discovering, developing and commercialising novel oral therapies for sleeprelated breathing diseases, especially obstructive sleep apnea (OSA). Its lead investigational drug candidate, AD109, is designed to address the underlying neuromuscular dysfunction that contributes to airway collapse during sleep, with the goal of offering a simpler treatment option to devices or surgery. The company emerged from research and aims to expand effective diagnosis and treatment reach for people living with OSA and similar conditions.Apnimed is seen as an innovative clinicalstage biotech in sleep medicine, generating strategic collaborations and funding to support latestage clinical development and potential regulatory submissions.Explore more
Apnimed Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apnimed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Apnimed has new funding data
Check if Apnimed has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Apnimed
Product Launch: Get notified when Apnimed launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Apnimed had a recent Job posting/layoffs
Apnimed, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Apnimed is spiking on competitors!
Earning: See what the market has to say on Apnimed recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Apnimed as Masked Content
Find 3 more new buyers
Compare Similar Companies to Apnimed
Compare insights from companies similar to Apnimed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apnimed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Apnimed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Apnimed.
Apnimed financials insights
Gather financial insights about Apnimed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$15M
2021
Series B
$25M
2023
Series C
$142.3M
2025
Debt
$23M
2026
Multiple Rounds
$367M
Apnimed Tech Stack
A closer look at the technologies used by Apnimed
Most Recent Scoops
Funding
Initial Public Offering (IPO)
IPO, Funding
Person-Based
Barriers
Person-Based
Financial Strategy
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Apnimed News & Media
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on August 31, 2026, the compensation committee of Apnimed’s board of directors granted 10 new non-executive employees non-qualified stock options to purchase an aggregatApnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apnimed closed its upsized IPO, including full exercise of the underwriters' option, raising $220.8M to advance its OSA pipeline.Apnimed raises USD 192m in IPO ahead of Q1 2027 sleep apnea drug decision - AllSci
Apnimed prices $192M IPO ahead of Q1 2027 FDA decision on lead sleep apnea drug candidate. Cambridge biotech eyes major market opportunity.The Startup Behind The Pill For Sleep Apnea Raises $192 Million In IPO - Forbes
Apnimed got a new CEO in anticipation of its public offering. Its pill for sleep apnea could receive approval early next year.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Apnimed
Sign Up For FreeTo access detailed company insights
Apnimed is a clinicalstage biopharmaceutical company focused on discovering, developing and commercialising novel oral therapies for sleeprelated breathing diseases, especially obstructive sleep apnea (OSA). Its lead investigational drug candidate, AD109, is designed to address the underlying neuromuscular dysfunction that contributes to airway col... Read More
